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Abstract
Improving upon the predictive validity of determining the transition from high risk to actual 
psychosis is a primary aim of early intervention research. Previous research has suggested that 
premorbid spontaneous dyskinesias may be one possible predictor. In this study, dyskinetic 
movements were assessed with the Abnormal Involuntary Movement Scale (AIMS) at baseline of 
a longitudinal study of 148 individuals at clinical high risk (CHR) of developing psychosis. 
Twenty-eight individuals transitioned to a psychotic disorder over the course of the study. Group 
comparisons between transitioned and non-transitioned individuals indicated that, relative to those 
that were not observed to transition, participants that developed a psychotic disorder exhibited 
greater spontaneous dyskinesias at baseline. Moreover, increased dyskinetic movements at 
baseline resulted in a more than two-fold increase in odds of developing a psychosis for each point 
increase in AIMS scale score. These findings suggest that individuals with greater premorbid 
dyskinetic movements may comprise a subset of CHR individuals at inordinate risk to 
decompensate into psychosis. Future work should employ assessments of spontaneous dyskinesias 
by instrumentation (e.g., electromyography) and look to ascertain whether specific dyskinesias 
(e.g., dystonia) or dyskinesias of specific body regions are associated with transitioning to 
psychosis.
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1. Introduction
Within the high risk literature, there is a major focus on identifying predictors of the 
transition to psychosis. Current estimates specify that, amongst individuals meeting formal 
operationalized criteria (e.g., Yung et al., 2005; McGlashan et al., 2010) for being at clinical 
high risk to develop psychosis (CHR), 36% will go on to develop a full-blown psychotic 
disorder within three years (Fusar-Poli et al., 2012). As part of this effort, premorbid 
movement abnormalities – namely hyperkinetic movements such as non-drug induced 
choreoathetoid and ballistic, dystonic, and stereotypic movements – which are collectively 
referred to as spontaneous dyskinesias have been suggested as potential predictors of 
psychotic transition. This is largely due to the presence of these behaviors among youth 
displaying other signs of psychosis-risk (MacManus et al., 2012), the prevalence of these 
symptoms among CHR individuals (Mittal et al., 2007), evidence from prospective and 
follow-back studies of motor abnormalities in those who go on to develop psychosis 
(Dickson et al., 2012; Rosso et al., 2000; Schiffman et al., 2004), and studies in which 
medication-free individuals with schizophrenia and other psychotic disorders exhibit 
dyskinetic movements across stages of illness (Whitty et al., 2009). The overlap between the 
neural substrate thought to underlie both dyskinesias and psychotic symptoms (Walker, 
1994) provides further support for dyskinesias as potential predictors of psychosis onset. In 
particular, and although not definitive, there is evidence that dopaminergic pathways within 
the striatum including dopamine neurons projecting from the ventral tegmental area to the 
nucleus accumbens and caudate nucleus as well as cortico-striato-pallido-thalamic pathways 
more generally are thought to give rise to both dyskinetic movements and psychotic 
symptomatology (e.g., Delong & Wichmann, 2007; Mittal et al., 2008; Walker et al., 1996).
Furthermore, Mittal and Walker (2007) evaluated dyskinetic movements as predictors of 
transition to psychosis within a CHR sample. This study found that dyskinesias of the face 
and upper body were associated with increased odds of developing a psychotic disorder. To 
our knowledge, the work by Mittal and Walker represents the only investigation of 
premorbid movement abnormalities as predictors of transition to psychosis within a CHR 
sample. Unfortunately, the prospect of confounding pharmacotherapy (i.e., drug-induced 
movement disorders) within their sample as well as the small subset of participants who 
transitioned to psychosis (n = 10) limits the extent to which the results of this work may be 
generalized. The present investigation, therefore, sought to confirm whether premorbid 
dyskinetic movements predict transition to psychosis using a large, neuroleptic-naïve CHR 
sample obtained from a multisite longitudinal study.
2. Method
2.1. Participants
The sample consisted of 148 individuals (86 male, 62 female) at CHR for psychosis. All 
participants were part of a longitudinal NIMH-funded study entitled “Enhancing the 
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Prospective Prediction of Psychosis” (PREDICT) that was conducted at the Universities of 
North Carolina at Chapel Hill, Toronto, and Yale to determine predictors of conversion to 
psychosis in individuals at CHR. All participants met the Criteria of Prodromal States 
(COPS) based on the Structured Interview for Psychosis-Risk Syndromes (SIPS; McGlashan 
et al., 2010). The sample had a mean age of 19.77 (4.60) years and the majority were 
Caucasian (77%). One hundred and forty-five (97.98%) met attenuated positive symptom 
syndrome (APSS) criteria, one (0.67%) met genetic risk and deterioration (GRD) criteria, 
and two (1.35%) met both APSS and GRD criteria. APSS includes the onset or worsening of 
non-psychotic level disturbances in thought content, thought processes, and/or perceptual 
abnormalities over the past year whereas GRD requires either a first degree relative with a 
psychotic disorder diagnosis or the participant having schizotypal personality disorder in 
conjunction with at least a 30% drop in functioning on the General Assessment of 
Functioning (GAF) scale over the past year.
Participants were excluded if they met criteria for any current or lifetime psychotic disorder, 
had a measured IQ < 70, had any history of central nervous system disorder or clinically 
significant head trauma, and if they had any current use of antipsychotic medication at 
baseline as well as if they received antipsychotic medication at any point during follow-up. 
Table 1 displays baseline psychotropic medication status for the sample.
2.2. Measures
Criteria for a psychosis-risk syndrome and for conversion to psychosis were determined 
using the SIPS and symptoms were assessed using the Scale of Psychosis-Risk Symptoms 
(SOPS; McGlashan et al., 2010). The Structured Interview for Axis I DSM-IV Disorders 
(SCID-I; First et al., 2002) was used to evaluate the presence of any Axis I disorder.
Dyskinetic movements were assessed using the Abnormal Involuntary Movement Scale 
(AIMS; Guy, 1976). The AIMS is a widely-used 10-item clinician-rated scale that evaluates 
aberrant movement in three body regions – the orofacial area (items 1–4; e.g., grimacing), 
extremities (items 5–6; e.g., athetoid movements of the hands), and trunk (item 7; e.g., 
shoulder rocking) – using a 0 (none/normal) to 4 (severe) scale. The AIMS includes three 
additional global evaluation items (8–10) that measure global severity of movements, 
incapacitation due to involuntary movements, and patient awareness of their dyskinesias, 
respectively. Apart from the individual item scores, the AIMS yields two scale scores: a 
total score including all 10 items and a non-global score which includes the seven behavior-
based ratings of abnormal movements (items 1–7) and excludes the three global evaluation 
items (8–10).
2.3. Procedure
The SIPS, SCID-I, and AIMS were administered at in-person baseline sessions. Raters were 
experienced research clinicians who demonstrated adequate reliability at routine SIPS and 
SCID-I reliability checks. The AIMS was administered by the same research clinicians and 
were trained to requisite reliability on the measure by review of a training tape and 
supervision of the study psychiatrist at each site. Post-training inter-rater agreement on 
determining initial eligibility and subsequent transition status was excellent (κ = 0.90). A 
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clinical psychologist or psychiatrist at each site conducted a comprehensive clinical 
assessment to determine if entry criteria were met. Inter-rater reliability for the SCID-I was 
determined at the start of the study and evaluated annually by 100% agreement on the 
diagnosis and at least 80% agreement for symptom presence. J.A. chaired weekly 
conference calls to review criteria for individuals admitted to the study. The study protocols 
and informed consents were reviewed and approved by the ethical review boards of all three 
study sites.
2.4. Statistical Analyses
None of the AIMS dependent variables satisfied the normality assumption for parametric 
statistics and were non-transformable by way of square, square root, and log methods. 
Moreover, there was a preponderance of zero values within the presented sample. 
Accordingly, nonparametric Mann-Whitney U tests were used for group comparisons 
between transitioned and non-transitioned individuals and the (x + 0.5) correction was 
applied to all AIMS variables (Yamamura, 1999). To quantify the predictive power of 
dyskinetic movements, continuous AIMS total and non-global scores were regressed on 
dichotomous psychosis transition status (non-transitioned vs. transitioned) in independent 
logistic regression analyses. Significant multicollinearity among several AIMS item scores 
precluded interpretation of multiple regression analyses. All analyses were conducted using 
SPSS (IBM Corp., 2012) and Stata/IC 10.0 software (StataCorp, 2007).
3. Results
Of the 148 CHR individuals, 28 (18.92%) made the transition to psychosis. Chi-square, U, 
and t tests indicated that the groups did not significantly differ in age (p = .86), sex (p = .33), 
ethnicity (p = .42), or educational attainment (p = .70). Further analyses indicated that there 
were no substantively significant demographic, clinical, or AIMS score difference between 
participants recruited through the three sites of this study and thus merger of the multisite 
data was justified.
3.1. Transition Group Differences in Abnormal Movements
Table 2 displays AIMS scores for the sample. A series of Mann-Whitney U tests indicated 
that participants who made the transition to psychosis demonstrated significantly more 
severe ratings than those who did not make the transition on AIMS total, non-global, 
severity of abnormal movements, and awareness of movements scores. Those who made the 
transition also had more severe ratings on specific indices of dyskinetic movements of the 
facial muscles, jaw, upper extremity, trunk, and, at a trend-level, movements of the tongue.
3.2. Abnormal Movements and Transition to Psychosis
Logistic regression analyses indicated that AIMS total (β = 0.81, SE = 0.28, Wald = 8.68, p 
< 0.01, OR = 2.25, 95% CI = 1.31–3.85) and non-global (β = 0.80, SE = 0.32, Wald = 6.29, 
p = 0.01, OR = 2.22, 95% CI = 1.19–4.15) scores were individually significant predictors of 
transition to psychosis. That is, elevated scores on the AIMS, indicative of greater dyskinetic 
movements, conferred a greater than two-fold multiplicative increase in odds of developing 
a psychotic disorder. Table 3 displays the probability of transitioning to psychosis for each 
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reported AIMS non-global score in our sample. The non-global score was selected as this 
index only includes the behavior-based ratings of abnormal movements (items 1–7) and not 
the global evaluation items (8–10) and is thus considered a relatively pure measure of 
dyskinetic movements.
4. Discussion
This multisite, longitudinal study investigated whether premorbid dyskinetic movements 
predict transitioning to psychosis among CHR individuals. The presence of dyskinetic 
movements within the presented neuroleptic-naïve CHR sample suggest that, although 
dyskinesias are well-documented pharmacologic sequelae, these movements may reflect a 
primary, rather than secondary, component of the psychosis disease process. This is 
consistent with multiple investigations of pre-psychosis individuals (Rosso et al., 2000; 
Walker et al., 1994) and psychotic disorder patients (Whitty et al., 2009) in which 
movement abnormalities were observed in the absence of antipsychotic medication. Viewed 
in this manner, dyskinetic movements may not only constitute potential predictors of 
psychosis onset but also comprise a set of symptoms that predate the onset of psychotic 
symptomatology and endure through the course of illness episodes thereby warranting 
independent clinical attention.
The observation of elevated baseline movement abnormalities for those that converted to 
psychosis relative to those that did not, in conjunction with the result that elevated 
dyskinetic movements induced a more than doubling of odds to develop a psychosis for each 
point increase in AIMS scores suggest that premorbid movement abnormalities may be used 
to enhance the prediction of psychosis onset. These findings closely mirror those of prior 
work in which dyskinetic movements singly (Mittal & Walker, 2007) or jointly with other 
risk factors (e.g., neurocognitive deficits; Mittal et al., 2010) have been shown to predict the 
onset of psychosis.
Interestingly, the presented pattern of results also fit with prior work documenting the 
predictive power of spontaneous dyskinesias within specific body regions. For example, 
across several investigations including samples of schizophrenia (Puri et al., 1999) and 
schizophrenia-spectrum disorder (Mittal et al., 2007; Walker et al., 1999) patients as well as 
CHR individuals (Mittal & Walker, 2007), dyskinetic movements in the facial and upper-
body regions have been shown to occur with greater frequency than dyskinesias of the 
lower-body (cf. Mittal et al., 2008). Similarly, our results indicated greater dyskinesias in the 
muscles of facial expression, jaw, tongue, upper extremity, and trunk within CHR 
individuals who transitioned to psychosis relative to those who did not. These findings 
should be viewed with caution as multicollinearity barred analysis of facial and upper-body 
region AIMS items as independent predictors of psychosis and correcting for Type I error 
across the family of group contrasts would exclude differences in dyskinesias of the tongue 
and facial muscles from conventional levels of statistical significance. Nonetheless, given 
that abnormal movements of the upper body and face, but not lower body, delineated at 
baseline those who do and do not transition to psychosis in this and at least one other study 
(Mittal & Walker, 2007), it is notable that the movement abnormalities that predate 
transitioning to psychosis may not be generalized motor problems but rather more 
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circumscribed profiles of facial and upper body motor dysregulation. These may reflect 
distinct underlying neuropathologies that match the topographical organization of the motor 
cortex and associated midbrain structures and thus point to specific neurocircuitries possibly 
implicated in the etiology and pathophysiology of psychosis (Lewis & Levitt, 2002; Walker, 
1994). Clearly, however, as these postulations remain highly speculative, further work is 
needed to elucidate the predictive validity of specific dyskinetic movements or dyskinesias 
in specific body regions with regards to psychosis onset and whether these behaviors share 
etiologic origins with psychotic symptomatology.
There are several limitations worth noting. First, our assessment of spontaneous dyskinesias 
was based upon a clinician-rated instrument. Although the AIMS is a widely used measure 
with adequate to good psychometric properties (Guy, 1976), there are notable drawbacks to 
using rating scales to assess movement abnormalities such as insensitivity of these measures 
to minor movement problems (Dean et al., 2004) and difficulties demarcating voluntary and 
involuntary dyskinetic movements. Accordingly, future studies should look to confirm the 
present findings using biotechnological devices (e.g., force gauges, position transducers, 
accelerometers, electromyography) to assess dyskinetic movements. As well, future studies 
should document any indications from participants clinical history or presentation (e.g., 
abrupt onset, inconsistent presence) that may serve to disambiguate whether the displayed 
movements have any volitional basis (Fahn, 2012). Second, although raters were trained to a 
high standard initially, ongoing assessment of reliability was not conducted in this study. 
Third, as shown in Table 3, only a minority of CHR individuals (n = 7) that transitioned to 
psychosis exhibited a non-zero AIMS non-global score. Although a greater proportion of 
transitioning (25%) than non-transitioning (8.33%) CHR individuals exhibited a non-zero 
AIMS non-global score, the statistical power of this sample is overtly limited and further 
work is clearly needed to provide more reliable and externally valid estimates of the 
increased odds of developing a psychosis given greater abnormal movements. Lastly, as is 
typical of longitudinal research, some CHR individuals discontinued participation in the 
study during follow-up and their omission may therefore bias the presented results.
In conclusion, the results of this study support a previous and smaller investigation positing 
premorbid dyskinetic movements as predictors of transition to psychosis among CHR 
individuals. This is significant in that individuals with spontaneous dyskinesias may 
represent a subset of the CHR population that is at particular risk to develop psychosis.
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Table 1
Psychotropic medications at baseline.
Medication Frequency (%)a
Transition to psychosis (n = 28) Non-transition to psychosis (n = 120)
None 22 (78.57%) 74 (61.67%)
Sertraline 3 (10.71%) 9 (7.50%)
Fluoxetine 1 (3.57%) 5 (4.17%)
Citalopram 1 (3.57%) 4 (3.33%)
Escitalopram Oxalate 1 (3.57%) 3 (2.50%)
Paroxetine 0 1 (0.83%)
Fluvoxamine 0 1 (0.83%)
Trazodone 1 (3.57%) 0
Venlafaxine 0 2 (1.67%)
Mirtazapine 0 2 (1.67%)
Bupropion 0 8 (6.67%)
Clonazepam 1 (3.57%) 4 (3.33%)
Lorazepam 0 2 (1.67%)
Alprazolam 0 1 (0.83%)
Methylphenidate 0 2 (1.67%)
Phentermine 0 1 (0.83%)
Atomoxetine 0 1 (0.83%)
a
Reported frequencies do not distinguish monotherapy and polypharmacy treatments (e.g., one CHR individual that transitioned to psychosis 
received combined trazodone, sertraline, and clonazepam treatment).
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Table 3
Risk of transitioning to psychosis associated with respective AIMS non-global scores.
AIMS Non-Global Score Full Sample n Transition Riska 95% CI Transitioned to Psychosis n
0 131 0.16 0.10 – 0.23 21
1 9 0.29 0.18 – 0.44 2
2 5 0.48 0.22 – 0.75 2
3 1 0.67 0.26 – 0.92 1
6 1 0.96 0.38 – 0.99 1
7 1 0.98 0.42 – 0.99 1
a
Probability of transitioning to psychosis given specified AIMS non-global score.
Schizophr Res. Author manuscript; available in PMC 2015 November 01.
